Cargando…

Increased incidence of Susac syndrome: a case series study

BACKGROUND: Susac syndrome (SuS) is a rare condition characterized by a clinical triad of sensorineural hearing loss, branch artery occlusion and encephalopathy. This study reports an increased incidence of SuS in Israel. We describe the clinical characteristics of these patients, diagnostic procedu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilf-Yarkoni, A., Elkayam, O., Aizenstein, O., Oron, Y., Furer, V., Zur, D., Goldstein, M., Barequet, D., Hallevi, H., Karni, A., Habot-Wilner, Z., Regev, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465403/
https://www.ncbi.nlm.nih.gov/pubmed/32878610
http://dx.doi.org/10.1186/s12883-020-01892-0
_version_ 1783577580026200064
author Wilf-Yarkoni, A.
Elkayam, O.
Aizenstein, O.
Oron, Y.
Furer, V.
Zur, D.
Goldstein, M.
Barequet, D.
Hallevi, H.
Karni, A.
Habot-Wilner, Z.
Regev, K.
author_facet Wilf-Yarkoni, A.
Elkayam, O.
Aizenstein, O.
Oron, Y.
Furer, V.
Zur, D.
Goldstein, M.
Barequet, D.
Hallevi, H.
Karni, A.
Habot-Wilner, Z.
Regev, K.
author_sort Wilf-Yarkoni, A.
collection PubMed
description BACKGROUND: Susac syndrome (SuS) is a rare condition characterized by a clinical triad of sensorineural hearing loss, branch artery occlusion and encephalopathy. This study reports an increased incidence of SuS in Israel. We describe the clinical characteristics of these patients, diagnostic procedures and the use and subsequent outcomes of newly published treatment guidelines. METHODS: This is a single center retrospective study. Patients who were diagnosed with SuS between July 2017 and August 2018 were enrolled in this study. RESULTS: Seven patients were diagnosed with SuS according to the diagnostic criteria in a time period of 13 months. The annual incidence was recently evaluated in Austria to be 0.024/100000, therefore, our case series represent at least a 5.4- fold increase in the annual incidence of SuS expected in Israel and a 7-fold increase in the annual incidence expected in our medical center. Mean time from the onset of the symptoms to diagnosis was three weeks and follow-up time was twenty four months. Recent exposure to cytomegalovirus was serologically evident in three patients and one patient had high titer of anti-streptolysin antibody. All patients underwent brain MRI, fluorescein angiography and audiometry. All patients were treated according to the newly recommended guidelines. All patients achieved clinical and radiological stability. CONCLUSIONS: We report of an increased incidence of SuS in Israel. Infectious serological findings may imply a post infectious mechanism. The use of the recommended diagnostic procedures reduced the time to diagnosis. Newly published treatment guidelines led to favorable clinical outcomes.
format Online
Article
Text
id pubmed-7465403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74654032020-09-02 Increased incidence of Susac syndrome: a case series study Wilf-Yarkoni, A. Elkayam, O. Aizenstein, O. Oron, Y. Furer, V. Zur, D. Goldstein, M. Barequet, D. Hallevi, H. Karni, A. Habot-Wilner, Z. Regev, K. BMC Neurol Research Article BACKGROUND: Susac syndrome (SuS) is a rare condition characterized by a clinical triad of sensorineural hearing loss, branch artery occlusion and encephalopathy. This study reports an increased incidence of SuS in Israel. We describe the clinical characteristics of these patients, diagnostic procedures and the use and subsequent outcomes of newly published treatment guidelines. METHODS: This is a single center retrospective study. Patients who were diagnosed with SuS between July 2017 and August 2018 were enrolled in this study. RESULTS: Seven patients were diagnosed with SuS according to the diagnostic criteria in a time period of 13 months. The annual incidence was recently evaluated in Austria to be 0.024/100000, therefore, our case series represent at least a 5.4- fold increase in the annual incidence of SuS expected in Israel and a 7-fold increase in the annual incidence expected in our medical center. Mean time from the onset of the symptoms to diagnosis was three weeks and follow-up time was twenty four months. Recent exposure to cytomegalovirus was serologically evident in three patients and one patient had high titer of anti-streptolysin antibody. All patients underwent brain MRI, fluorescein angiography and audiometry. All patients were treated according to the newly recommended guidelines. All patients achieved clinical and radiological stability. CONCLUSIONS: We report of an increased incidence of SuS in Israel. Infectious serological findings may imply a post infectious mechanism. The use of the recommended diagnostic procedures reduced the time to diagnosis. Newly published treatment guidelines led to favorable clinical outcomes. BioMed Central 2020-09-02 /pmc/articles/PMC7465403/ /pubmed/32878610 http://dx.doi.org/10.1186/s12883-020-01892-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wilf-Yarkoni, A.
Elkayam, O.
Aizenstein, O.
Oron, Y.
Furer, V.
Zur, D.
Goldstein, M.
Barequet, D.
Hallevi, H.
Karni, A.
Habot-Wilner, Z.
Regev, K.
Increased incidence of Susac syndrome: a case series study
title Increased incidence of Susac syndrome: a case series study
title_full Increased incidence of Susac syndrome: a case series study
title_fullStr Increased incidence of Susac syndrome: a case series study
title_full_unstemmed Increased incidence of Susac syndrome: a case series study
title_short Increased incidence of Susac syndrome: a case series study
title_sort increased incidence of susac syndrome: a case series study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465403/
https://www.ncbi.nlm.nih.gov/pubmed/32878610
http://dx.doi.org/10.1186/s12883-020-01892-0
work_keys_str_mv AT wilfyarkonia increasedincidenceofsusacsyndromeacaseseriesstudy
AT elkayamo increasedincidenceofsusacsyndromeacaseseriesstudy
AT aizensteino increasedincidenceofsusacsyndromeacaseseriesstudy
AT orony increasedincidenceofsusacsyndromeacaseseriesstudy
AT furerv increasedincidenceofsusacsyndromeacaseseriesstudy
AT zurd increasedincidenceofsusacsyndromeacaseseriesstudy
AT goldsteinm increasedincidenceofsusacsyndromeacaseseriesstudy
AT barequetd increasedincidenceofsusacsyndromeacaseseriesstudy
AT hallevih increasedincidenceofsusacsyndromeacaseseriesstudy
AT karnia increasedincidenceofsusacsyndromeacaseseriesstudy
AT habotwilnerz increasedincidenceofsusacsyndromeacaseseriesstudy
AT regevk increasedincidenceofsusacsyndromeacaseseriesstudy